Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma

E. E. Warry, Jennifer Willcox, S. E. Suter

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Peripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with B-cell lymphoma. Objective: To examine apheresis and PBHCT outcomes in dogs diagnosed with T-cell lymphoma (TCL). Animals: Fifteen client-owned dogs diagnosed with high-grade TCL. Methods: After high-dose cyclophosphamide and rhG-colony-stimulating (rhG-CSF) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment. Results: More than 2 × 106 CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B-cell lymphoma 120 days post-PBHCT. The median disease-free interval and overall survival (OS) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS. Two of 13 (15%) dogs were alive 741 and 772 days post-PBHCT. Conclusions and Clinical Importance: PBHCT may be considered as a treatment option for dogs with TCL.

Original languageEnglish (US)
Pages (from-to)529-537
Number of pages9
JournalJournal of Veterinary Internal Medicine
Volume28
Issue number2
DOIs
StatePublished - Mar 1 2014
Externally publishedYes

Fingerprint

cell transplantation
T-Cell Lymphoma
Cell Transplantation
lymphoma
Blood Cells
T-lymphocytes
Dogs
dogs
blood
B-Cell Lymphoma
B-lymphocytes
Blood Component Removal
separators
cyclophosphamide
Whole-Body Irradiation
remission
cells
mononuclear leukocytes
dosage
Non-Hodgkin's Lymphoma

Keywords

  • Apheresis
  • Bone marrow transplantation
  • CD34+
  • Engraftment
  • Total body irradiation

ASJC Scopus subject areas

  • veterinary(all)
  • Medicine(all)

Cite this

Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma. / Warry, E. E.; Willcox, Jennifer; Suter, S. E.

In: Journal of Veterinary Internal Medicine, Vol. 28, No. 2, 01.03.2014, p. 529-537.

Research output: Contribution to journalArticle

@article{c8c7650adcd8498e90bd16fe7b5f7674,
title = "Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma",
abstract = "Background: Peripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with B-cell lymphoma. Objective: To examine apheresis and PBHCT outcomes in dogs diagnosed with T-cell lymphoma (TCL). Animals: Fifteen client-owned dogs diagnosed with high-grade TCL. Methods: After high-dose cyclophosphamide and rhG-colony-stimulating (rhG-CSF) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment. Results: More than 2 × 106 CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87{\%}) dogs engrafted appropriately, whereas 2 (13{\%}) of the dogs died in the hospital. One dog developed cutaneous B-cell lymphoma 120 days post-PBHCT. The median disease-free interval and overall survival (OS) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS. Two of 13 (15{\%}) dogs were alive 741 and 772 days post-PBHCT. Conclusions and Clinical Importance: PBHCT may be considered as a treatment option for dogs with TCL.",
keywords = "Apheresis, Bone marrow transplantation, CD34+, Engraftment, Total body irradiation",
author = "Warry, {E. E.} and Jennifer Willcox and Suter, {S. E.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1111/jvim.12302",
language = "English (US)",
volume = "28",
pages = "529--537",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma

AU - Warry, E. E.

AU - Willcox, Jennifer

AU - Suter, S. E.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Background: Peripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with B-cell lymphoma. Objective: To examine apheresis and PBHCT outcomes in dogs diagnosed with T-cell lymphoma (TCL). Animals: Fifteen client-owned dogs diagnosed with high-grade TCL. Methods: After high-dose cyclophosphamide and rhG-colony-stimulating (rhG-CSF) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment. Results: More than 2 × 106 CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B-cell lymphoma 120 days post-PBHCT. The median disease-free interval and overall survival (OS) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS. Two of 13 (15%) dogs were alive 741 and 772 days post-PBHCT. Conclusions and Clinical Importance: PBHCT may be considered as a treatment option for dogs with TCL.

AB - Background: Peripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with B-cell lymphoma. Objective: To examine apheresis and PBHCT outcomes in dogs diagnosed with T-cell lymphoma (TCL). Animals: Fifteen client-owned dogs diagnosed with high-grade TCL. Methods: After high-dose cyclophosphamide and rhG-colony-stimulating (rhG-CSF) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment. Results: More than 2 × 106 CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B-cell lymphoma 120 days post-PBHCT. The median disease-free interval and overall survival (OS) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS. Two of 13 (15%) dogs were alive 741 and 772 days post-PBHCT. Conclusions and Clinical Importance: PBHCT may be considered as a treatment option for dogs with TCL.

KW - Apheresis

KW - Bone marrow transplantation

KW - CD34+

KW - Engraftment

KW - Total body irradiation

UR - http://www.scopus.com/inward/record.url?scp=84897629516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897629516&partnerID=8YFLogxK

U2 - 10.1111/jvim.12302

DO - 10.1111/jvim.12302

M3 - Article

C2 - 24467413

AN - SCOPUS:84897629516

VL - 28

SP - 529

EP - 537

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 2

ER -